6549.TWO TaiwanJ Pharmaceuticals Co., Ltd.
- Market cap
- TWD 484M
- P/E
- -
- P/B
- 7.45x
- ROE
- -34.3%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Dec 2025.
Is 6549.TWO undervalued?
Graham numberThe Graham number of TaiwanJ Pharmaceuticals Co., Ltd. cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
TaiwanJ Pharmaceuticals Co., Ltd. fundamental analysis
No fundamental analysis for TaiwanJ Pharmaceuticals Co., Ltd. yet.
TaiwanJ Pharmaceuticals Co., Ltd. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About TaiwanJ Pharmaceuticals Co., Ltd.
TaiwanJ Pharmaceuticals Co., Ltd., a specialty pharmaceutical company, develops and commercializes small molecules for chronic organ inflammation of metabolic, autoimmune, and infectious etiologies in Taiwan. The company develops JKB-122 and JKB-121; and novel chemical entities for therapy to address chronic liver diseases and allergy/asthma. Its products target various diseases that include liver inflammation/liver fibrosis, non-alcoholic steatohepatitis, non-alcoholic fatt…
Full company profileTaiwanJ Pharmaceuticals Co., Ltd. financial statements
TaiwanJ Pharmaceuticals Co., Ltd. annual financial statements (TWD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Income Statement | |||||||
| Revenue | 61.7M | - | 22.1M | 15.4M | 22.7M | 0.00 | 0.00 |
| Gross Profit | 41.4M | -1.41M | 22.1M | -59.9M | 22.7M | -1.89M | 0.00 |
| Operating Income | -6.69M | -42.4M | -9.73M | -96.4M | -6.61M | -27.0M | -25.2M |
| EBITDA | 21.7M | -41.0M | -9.15M | -16.0M | -1.74M | -20.4M | -22.7M |
| Net Income | -5.08M | -42.5M | -12.4M | -92.5M | -6.05M | -22.3M | -24.3M |
| EPS | -0.07 | -0.60 | -0.17 | -1.23 | -0.08 | -0.29 | -0.30 |
| Balance Sheet | |||||||
| Total Assets | 160M | 183M | 170M | 79.8M | 73.6M | 101M | 77.2M |
| Total Liabilities | 8.21M | 7.28M | 6.85M | 8.19M | 6.62M | 5.71M | 6.33M |
| Shareholders' Equity | 152M | 176M | 163M | 71.6M | 66.9M | 95.1M | 70.9M |
| Cash & Short-term Investments | 12.2M | 93.4M | 82.9M | 60.7M | 58.8M | 87.6M | 67.8M |
| Total Debt | 890K | 890K | 331K | 1.86M | 1.17M | 472K | - |
| Cash Flow | |||||||
| Operating Cash Flow | 16.9M | -41.3M | -10.0M | -21.1M | -821K | -22.6M | -24.2M |
| Capital Expenditure | 1.47M | 1.43M | 0.00 | 1.23M | 1.44M | 0.00 | 286K |
| Free Cash Flow | 15.4M | -42.7M | -10.0M | -22.3M | -2.26M | -22.6M | -24.5M |
| Ratios | |||||||
| ROE | -3.4% | -24.1% | -7.6% | -129.1% | -9.0% | -23.5% | -34.3% |
| ROA | -3.2% | -23.2% | -7.3% | -115.9% | -8.2% | -22.2% | -31.5% |
| Net Profit Margin | -8.2% | - | -56.3% | -602.2% | -26.6% | - | - |
| Debt to Equity | 0.01x | 0.01x | 0.00x | 0.03x | 0.02x | 0.00x | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
TaiwanJ Pharmaceuticals Co., Ltd. dividends
TaiwanJ Pharmaceuticals Co., Ltd. has not paid dividends in the last 7 fiscal years.
Who owns TaiwanJ Pharmaceuticals Co., Ltd.
Ownership data of TaiwanJ Pharmaceuticals Co., Ltd. is not available yet.
TaiwanJ Pharmaceuticals Co., Ltd. company profile
- Company name
- TaiwanJ Pharmaceuticals Co., Ltd.
- Ticker
- 6549.TWO
- ISIN
- TW0006549009
- Exchange
- Taiwan OTC Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 13
- Fiscal year end
- December
- Address
- No.2 ShengYi Road, Zhubei, Taiwan, 302058
- Phone
- 886 3 658 7721
- Website
- taiwanj.com
About TaiwanJ Pharmaceuticals Co., Ltd.
TaiwanJ Pharmaceuticals Co., Ltd., a specialty pharmaceutical company, develops and commercializes small molecules for chronic organ inflammation of metabolic, autoimmune, and infectious etiologies in Taiwan. The company develops JKB-122 and JKB-121; and novel chemical entities for therapy to address chronic liver diseases and allergy/asthma. Its products target various diseases that include liver inflammation/liver fibrosis, non-alcoholic steatohepatitis, non-alcoholic fatty liver disease, autoimmune diseases, asthma, and atopic dermatitis. The company was incorporated in 2011 and is based in Zhubei, Taiwan.
TaiwanJ Pharmaceuticals Co., Ltd. management
3- Mr. Hung-Chang YuanGM & Director
- Dr. Edwin Wu Ph.D.Founder & Honorary Chairman
- Mr. Zhi Jie GuoAccounting Supervisor